IWM
VVOS icon

IHT Wealth Management’s Vivos Therapeutics VVOS Stock Holding History

IHT Wealth Management’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.9K Buy
76,736
+35,675
+87% +$28K ﹤0.01% 1224
2026
Q1 		$48.5K Buy
+41,061
New +$65.8K ﹤0.01% 1230
2021
Q3 		– Sell
-493
Closed -$61K – 981
2021
Q2 		$61K Buy
+493
New +$80.3K ﹤0.01% 920

Other funds holding VVOS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

IHT Wealth Management's VVOS Position: Q2 2026 in Review

IHT Wealth Management increased its Vivos Therapeutics (VVOS) stake by 87% in Q2 2026, buying an estimated $28K and bringing the position to 76,736 shares worth $34.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1224.

IHT Wealth Management first reported a position in VVOS in Q2 2021 and has held it in 3 quarters since. The position peaked at $61K in Q2 2021. 23 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

  • IHT Wealth Management held 76,736 shares of Vivos Therapeutics worth $34.9K as of Q2 2026.
  • IHT Wealth Management bought 35,675 Vivos Therapeutics shares in Q2 2026, an estimated $28K.
  • Vivos Therapeutics made up ﹤0.01% of IHT Wealth Management's portfolio in Q2 2026, its #1224 holding.
  • IHT Wealth Management first reported a position in Vivos Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • IHT Wealth Management's Vivos Therapeutics position peaked at $61K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on IHT Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.